Please assess the completion status of the following clinical trial:

Trial Title: MSG Use With 18F-DCFPyL PET/CT Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known prostate cancer with biochemical recurrence after initial curative therapy with radical prostatectomy, presenting with a prostate specific antigen (PSA) greater than 0.4 ng/mL.~* Subjects with findings on other examinations (such as plain x-ray, CT, MRI or bone scintigraphy and others) that are suspicious for metastatic disease but not conclusively diagnostic of metastatic disease, within 3 months of PET scan.~* Known prostate cancer with biochemical recurrence after initial curative therapy with radiation therapy (including brachytherapy), with a PSA level \>2 ng/mL above the nadir after radiation therapy.~* Castration resistant prostate cancer with a minimum PSA of 2.0 ng/mL with 2 consecutive rises above the nadir and castrate levels of testosterone (\<1.7 nmol/L). Treatment does not need to be discontinued before the 18F-DCFPyL scan.~* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.~Exclusion Criteria:~* Medically unstable (eg. acute illness, unstable vital signs)~* Unable to lie supine for the duration of imaging~* Unable to provide written consent~* Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)~* Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible~* History of severe asthma that has led to hospitalizations or emergency room visits~* History of intolerance to MSG~* History of severe headaches or migraines triggered by food or MSG~* Participants on a sodium/salt restricted diet due to other medical conditions~* No new treatment has started between the first and second 18F-DCFPyL PET/CT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-DCFPyL PET/CT scan with MSG drink (Type: EXPERIMENTAL): Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
- 18F-DCFPyL PET/CT scan with placebo drink (Type: PLACEBO_COMPARATOR): Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).